Q4 2019 EPS Estimates for Collegium Pharmaceutical Inc (NASDAQ:COLL) Reduced by Analyst

Collegium Pharmaceutical Inc (NASDAQ:COLL) – Investment analysts at William Blair reduced their Q4 2019 earnings estimates for shares of Collegium Pharmaceutical in a research report issued to clients and investors on Tuesday, July 16th. William Blair analyst T. Lugo now expects that the specialty pharmaceutical company will post earnings of $0.42 per share for the quarter, down from their prior estimate of $0.43.

Several other equities research analysts have also weighed in on the company. HC Wainwright restated a “buy” rating on shares of Ballard Power Systems in a report on Friday, May 3rd. ValuEngine lowered Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Cantor Fitzgerald set a $135.00 target price on Zimmer Biomet and gave the stock a “buy” rating in a report on Friday, April 26th. Janney Montgomery Scott initiated coverage on PLx Pharma in a report on Friday, April 12th. They issued a “buy” rating for the company. Finally, BidaskClub lowered Zebra Technologies from a “buy” rating to a “hold” rating in a report on Tuesday. Three research analysts have rated the stock with a sell rating and five have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $26.17.

Shares of COLL opened at $10.35 on Thursday. The stock has a market cap of $345.56 million, a P/E ratio of -8.70 and a beta of 0.55. Collegium Pharmaceutical has a 52-week low of $10.18 and a 52-week high of $21.20. The company has a 50-day moving average of $12.03. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.24 and a quick ratio of 1.19.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Wednesday, May 8th. The specialty pharmaceutical company reported ($0.29) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.01. The company had revenue of $74.52 million during the quarter, compared to the consensus estimate of $70.10 million. Collegium Pharmaceutical had a negative return on equity of 30.87% and a negative net margin of 10.36%.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in COLL. Macquarie Group Ltd. raised its stake in shares of Collegium Pharmaceutical by 8.7% in the 4th quarter. Macquarie Group Ltd. now owns 2,759,007 shares of the specialty pharmaceutical company’s stock valued at $47,372,000 after acquiring an additional 221,779 shares during the period. BlackRock Inc. raised its position in Collegium Pharmaceutical by 8.7% in the 4th quarter. BlackRock Inc. now owns 2,619,718 shares of the specialty pharmaceutical company’s stock worth $44,980,000 after purchasing an additional 210,145 shares during the period. Millennium Management LLC raised its position in Collegium Pharmaceutical by 863.4% in the 4th quarter. Millennium Management LLC now owns 1,305,001 shares of the specialty pharmaceutical company’s stock worth $22,407,000 after purchasing an additional 1,169,537 shares during the period. Rice Hall James & Associates LLC raised its position in Collegium Pharmaceutical by 27.8% in the 1st quarter. Rice Hall James & Associates LLC now owns 1,191,141 shares of the specialty pharmaceutical company’s stock worth $18,034,000 after purchasing an additional 259,015 shares during the period. Finally, Cortina Asset Management LLC raised its position in Collegium Pharmaceutical by 81.0% in the 2nd quarter. Cortina Asset Management LLC now owns 509,701 shares of the specialty pharmaceutical company’s stock worth $6,703,000 after purchasing an additional 228,035 shares during the period. Hedge funds and other institutional investors own 94.83% of the company’s stock.

In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 2,857 shares of the company’s stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $12.31, for a total value of $35,169.67. Following the sale, the executive vice president now owns 40,596 shares in the company, valued at approximately $499,736.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Michael Thomas Heffernan sold 25,000 shares of the company’s stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $12.84, for a total value of $321,000.00. Following the completion of the sale, the director now owns 188,586 shares in the company, valued at approximately $2,421,444.24. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 91,144 shares of company stock valued at $1,075,506. Corporate insiders own 8.08% of the company’s stock.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.

Recommended Story: Fiduciary

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.